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Abstract: Bronchial asthma is often accompanied with allergic rhinitis or chronic
sinusitis. Mucosal abnormalities of sinonasal cavity may influence lower respiratory
responses in patients with asthma. We experienced a case of 72-year-old woman with
asthma, who had dyspnea on exertion and a large volume of expectoration of more
than 100m.l! a day. Furthermore she had nasal symptoms (nasal obstruction and
rhinorrea) with prominent post-nasal discharge. Computed tomography (cT) scans of
sinonasal cavity revealed marked thickness of nasal mucosa. Although her asthma
. symptoms such as wheezing and dyspnea improved by administration of
bronchodialators, antiallergic agent, and beclomethason di isocyanate (BOI) accompa-
nied with spa therapy after admission, the volume of expectoration revealed no
decrease and her peak expiratory flow (PEF) didn't increase. The volume of expectora-
tion and the PEF showed marked improvement after starting of intranasal
glucocorticoid therapy. It is suggested from her clinical course that treatment with
intranasal glucocorticoids is very important in asthmatic patients with mucosal
abnormalities of sinonasal cavity.
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Introduction
Bronchial asthma IS classified into three
fundamental types I a. simple bron-
choconstriction type, I b. bronchoconstric-
tion +hypersecretion type, and IT. Broncho-
constriction type, according to clinical symp-
toms and findings 1- 3). Among these clinical
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asthma types, I b. (hypersecretion) asthma
is closely related to eosinophilia In the
airways4), and it is difficult to control
hepersecretion without systemic gluco-
corticoid therapy.
Bronchial asthma IS often accompanied
with allergic rhinitis or chronic sinusitis.
However, the influences of mucosal abnor-
malities of sinonasal cavity in these disease
on the pathogenesis of asthma are poorly
understood. Sinusitis IS more commonly
observed in allergic individuals than in nor-
mal subjects s. 6). It has been reported that
intranasal glucocorticoids during pollen sea-
sons reduce asthma symptoms 7. 8), and de-
crease bronchial reactivity in pollen-allergic
asthmatics'). These findings suggests that
allergic rhinitis or chronic sinusitis influences
the pathophysiological changes in the airways
of bronchial asthma. In this article, we
reported a case with type I b asthma whose
hypersecretion improved by the use of
intranasal corticosteroids.
Case Report
A 72-year-old woman with asthma was
admitted to Misasa Medical Branch because
of severe continuous attacks accompanied
with hypersecretion. She had no dyspnea until
the age of 52. When she was 52 years old, she
had slight dyspnea and wheeze after she
suffering from common cold. She subse-
quently consulted a doctor, and was diag-
nosed as bronchial asthma. Since then, she
had asthma attacks several times a year,
however, she had no therapy for bronchial
asthma. In 1989, She had undergone left
mammectomy because of mastocarcinoma.
After the operation, she often had suffered
from asthma attacks. Recently she had
dyspnea on exertion and a large volume of
expectoration.
On admission at our hospital, the physical
examination revealed prominent post-nasal
discharge and marked decrease of breath
sound at the both lower lung fields. The
findings of blood chemistry and urinalysis
were normal. The serum IgE level was 150.8
IU/mP and no specific antibody for inhaled
allergen were detected by multiple antigen
simultaneous test (MAST). Results of respi-
ratory function tests were as follows; %VC
. .
85.2%, FEV1.0% 57.2%, %V75 25.7%, %V50
.
20.2% and %V25 19.9%.
A chest X-ray showed neither sign of dif-
fuse panbronchiolitis nor pulmonary emphy-
sema (Fig. 1). A computed tomography
(CT) scan revealed marked mucosal thicken-
ing in bilateral nasal cavity (Fig. 2).
Her clinical course is shown in Fig. 3.
After admission, she was underwent complex
spa therapy (swimming training in a hot
spring pool + inhalation of iodine salt
solution +fango therapy) with inhaled
glucocorticoid (BDI 200m9/day), anti-allergic
agent and bronchodialators. No apparent
improvement in dose of expectoration (more
than 100mP/day) was found despite gradual
improvement of dyspnea. The peak expiratory
Figure 1 Chest radiograph on admission
showing normal findings
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Discussion
Our prevIOus studies have shown that
bronchial asthma is classified into three
Figure 3 Clinical course of patient during
admission at our hospital
types according to the clinical symptoms
caused by the pathophysiological changes
In the airways 1-3). In patients with
hypersecretion type, mucosal abnormalities of
sinonasal cavity is often observed, suggesting
that pathophysiological changes in sinonasal
mucosa may influence aIrway responses in
patients.
In this article, we presented a case with
hypersecretion type asthma and a low value
of PEF, which were improved by intranasal
steroid therapy. The volume of post-nasal
discharge and expectoration in this patient
clearly decreased after the intranasal steroid
therapy. This most likely indicates that
post-nasal discharge from mucosal disorders
of sinonasal cavity influences the patho-
phisiology of aIrways, leading to hyper-
secretion.
Regarding airway responses, intranasal
steroid therapy improved morning PEF; the
value PEF increased from 120 ± 20 L/m to
210 ± 20 L/m after intranasal steroid ther-
apy. The improvement of PEF may be associ-
ated with the decrease in nasal discharge. It
has been reported that nasal inflammation
may lead to exacerbation of asthma symp-
toms by inducing increased bronchial reactivi-
ty 10). The treatment with intranasal glu-
cocorticoids during pollen season reduces
asthma symptoms 1. 8) and suppresses upper
and lower airway responses to cat expo-
sure II). These observations indicate that nasal
inflammation changes bronchial reactivity
and exacerbate asthma symptoms. In many
of patients with chronic sinusitis, eosinophil
infiltration in sinus mucosa has been ob-
served, and extracellular deposition of major
basic protein (~BP) has also been shown to
correlate with mucosal damage 6). This may
suggest the possibility that eosinophils in
Figure 2 CT scans of the SinUS level.
~arked thickenings of nasal
mucosa were observed.
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flow (PEF) (80 - 130 R / min) in the early
morning did not improved. To improve post-
nasal discharge, intranasal steroid (fultica-
sone) was started to be administered on the
37th hospital day. As shown in figure 3, the
volume of expectoration gradually decreased,
accompanied with improvement of PEF.
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Table 1. Laboratory Findings on Admis-
slOn
Hematological findings Sodium 146.8mmoVL
White blood cell Potassium 3.9BmmollL
5,OOO/mm3 Chloride 105.7 mmollL
lymph. 31_5% Blood urea nitrogen 13.7 mgldL
mono. 7.5% Creatinine 0.9 mgldL
nautre. 59.5% Uric Acid 6.5 mgldL
eosino. 1.5%
Red blood cell 418x10(/~L Immunological findings
Hemoglobin 15.1 gldL IgE(RIST) 15O.801UlmL
Hematocrit 43.7% IgE(RAST)
Platelet 14.1x104/IlL D. pteronyssinus score 0
ESR 6 rnmJh D. farinae score a
HD1 score 0
Blood chemistry HD2 score 0
Total protein 7.4 gldL Cockroach score 0
Albumin 5.1 gldL Candida albicans score 0
AlG 2.23 IgE(MAST)
y-grobulin 14.2% Inhalation allergens all negative
GOT 26 lUlL
GPT 6 lUlL Respiratory function test
ALP 94 lUlL FVC 1.80L
LDH 207 lUlL %FVC 86.2%
y·GTP 18 lUlL FEV1.0 1.03 L
Total cholesterol 175 mgldL FEV1.0% 57.2%
Triglyceride 56 mgldL
nasal discharge aspirated into aIrways make
damages to bronchial mucosa.
CT scans brings a lot of imagings of nasal
cavity and paranasal sinuses 12). Studies on
CT scans of patients with chronic sinusitis
have shown that many of subjects with
extensive mucosal thickening and ostiomeatal
complex change are associated with asth-
ma 13). The pathophysiology of asthma may
change related to nasal inflammation, and
nasal disorder can lead to impairment of
bronchial mucosa In asthma.
In fact, from the course of this case,
intranasal glucocorticoid therapy would be
expected to improve asthma symptoms In
patients with chronic sinusitis or allergic
rhinitis.
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気管支喋息症例に対する鼻腔内ステロイド療法
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気管支喋息症例には,アレルギー性鼻炎や慢性
副鼻腔炎の合併が認められる｡鼻腔内への吸入ス
テロイド投与が瑞息症状を改善したという報告も
存在し,鼻腔病変が下気道の反応に何らかの影響
を及ぼしている可能性が考えられる｡今回,気管
支喋息にて入院した72才の女性の症例を呈示する｡
労作性呼吸困難と多量の噂疾排出が認められ,入
院後の投薬や温泉療法にて呼吸困難は改善したが,
噂疾排出は減少せず,ピークフロー値も上昇が認
められなかった｡明らかな後鼻漏が認められ,C
Tにて両側鼻腔粘膜の著明な肥厚の所見が見られ
たため,鼻腔内吸入ステロイド投与を開始した｡
開始後,喝疾排出量,ピークフロー値は著明な改
善を示した｡この症例のように,鼻腔あるいは副
鼻腔に対する治療が瑞息症状を改善する症例が存
在する可能性が考えられた｡
索引用語 :気管支瑞息,鼻炎,鼻腔内吸入ステロ
イド療法,喝疾排出,ピークフロー
